Skip to Content
MilliporeSigma
  • Cysteine Deprivation Targets Ovarian Clear Cell Carcinoma Via Oxidative Stress and Iron-Sulfur Cluster Biogenesis Deficit.

Cysteine Deprivation Targets Ovarian Clear Cell Carcinoma Via Oxidative Stress and Iron-Sulfur Cluster Biogenesis Deficit.

Antioxidants & redox signaling (2020-04-28)
Wisna Novera, Zheng-Wei Lee, Dawn Sijin Nin, Melvin Zi-Yu Dai, Shabana Binte Idres, Hui Wu, J Mirjam A Damen, Tuan Zea Tan, Arthur Yi Loong Sim, Yun Chau Long, Wei Wu, Ruby Yun-Ju Huang, Lih-Wen Deng
ABSTRACT

Aims: Current treatment options for ovarian clear cell carcinoma (OCCC) are limited to combination of platinum-based and other cytotoxic agents to which patients respond poorly due to intrinsic chemoresistance. There is therefore an urgent need to develop alternative therapeutic strategies for OCCC. Results: Cysteine deprivation suppresses OCCC growth in vitro and in vivo with no apparent toxicity. Modes of cell death induced by cysteine deprivation in OCCC are determined by their innate metabolic profiles. Cysteine-deprived glycolytic OCCC is abolished primarily by oxidative stress-dependent necrosis and ferroptosis, which can otherwise be prevented by pretreatment with antioxidative agents. Meanwhile, OCCC that relies on mitochondria respiration for its bioenergetics is suppressed through apoptosis, which can otherwise be averted by pretreatment with cysteine precursor alone, but not with antioxidative agents. Cysteine deprivation induces apoptosis in respiring OCCC by limiting iron-sulfur (Fe-S) cluster synthesis in the mitochondria, without which electron transport chain may be disrupted. Respiring OCCC responds to Fe-S cluster deficit by increasing iron influx into the mitochondria, which leads to iron overload, mitochondria damage, and eventual cell death. Innovation/Conclusion: This study demonstrates the importance of cysteine availability in OCCC that is for its antioxidative property and its less appreciated role in mitochondria respiration. Regardless of OCCC metabolic profiles, cysteine deprivation abolishes both glycolytic and respiring OCCC growth in vitro and in vivo. Conclusion: This study highlights the therapeutic potential of cysteine deprivation for OCCC.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
D-Lactic Dehydrogenase from Lactobacillus leichmannii, lyophilized powder, 150-500 units/mg protein
Sigma-Aldrich
Amyloid Protein Non-Aβ Component, ≥80% (HPLC)
Sigma-Aldrich
DL-Propargylglycine, cystathionine γ-lyase inhibitor
Sigma-Aldrich
Isocitric Dehydrogenase (NADP) from porcine heart, Type I, 0.5-3.0 unit/mg solid (plus numerous enzyme activities associated with porcine heart)
Sigma-Aldrich
Propidium iodide, ≥94.0% (HPLC)
Sigma-Aldrich
Deferoxamine mesylate salt, powder, ≥92.5% (TLC)
Sigma-Aldrich
2′,7′-Dichlorodihydrofluorescein diacetate, ≥97%
Sigma-Aldrich
Ninhydrin, ACS reagent
Sigma-Aldrich
2,2′-Bipyridyl, ReagentPlus®, ≥99%
Sigma-Aldrich
N-Acetyl-L-cysteine, Sigma Grade, ≥99% (TLC), powder
Sigma-Aldrich
Sulfasalazine, 97.0-101.5%
Sigma-Aldrich
Glutathione Reductase from baker′s yeast (S. cerevisiae), ammonium sulfate suspension, 100-300 units/mg protein (biuret)
Sigma-Aldrich
Ammonium iron(II) sulfate hexahydrate, 99.997% trace metals basis
Sigma-Aldrich
(±)-6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid, 97%
Sigma-Aldrich
(R)-MG132